CEO Sergio Traversa was paid $8,892,633 in fiscal year 2025, ↑ up 393.8% from fiscal year 2024 (SEC filing 0001213900-26-045192 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,892,633 ↑ Sergio Traversa total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 42.66% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
RLMD's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sergio Traversa | $787,787 | $2,103,545 | $0 | $4,951,301 | $0 | $0 | $1,050,000 | $8,892,633 |
| Chief Executive Officer | ||||||||
| Maged Shenouda | 558,990 | 1,581,644 | 0 | 3,450,819 | 0 | 0 | 500,000 | 6,091,453 |
| Chief Financial Officer | ||||||||
| Charles Ence | 548,990 | 1,119,217 | 0 | 3,328,819 | 0 | 0 | 500,000 | 5,497,026 |
| Chief Accounting and Compliance Officer | ||||||||
| Paul Kelly | 499,800 | 1,085,480 | 0 | 3,328,819 | 0 | 0 | 375,000 | 5,289,099 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sergio Traversa | $8,892,633 | $1,800,723 | $2,071,096 | ↑ +7,091,910 |
| Maged Shenouda | 6,091,453 | 993,750 | 1,182,754 | ↑ +5,097,703 |
| Charles Ence | 5,497,026 | 983,039 | 1,170,379 | ↑ +4,513,987 |
| Paul Kelly | 5,289,099 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Relmada Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper RLMD reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name RLMD as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Charles J. Casamento | Chair of the Board | $353,608 |
| Fabiana Fedeli | Independent Director | $290,638 |
| John Glasspool | Independent Director | $286,518 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sergio Traversa | Option | 91,941 | 2.48 | — |
| Charles Ence | Option | 350,000 | 0.67 | — |
| Paul Kelly | RSU | 7,316,336 | — | 6,281,367 |
| Paul Kelly | Option | 32,836 | 2.48 | — |
| Maged Shenouda | Option | 112,500 | 3.37 | — |
| Charles Ence | Option | 41,045 | 2.48 | — |
| Sergio Traversa | Option | 192,500 | 3.37 | — |
| Maged Shenouda | Option | 525,000 | 0.67 | — |
| Maged Shenouda | Option | 828,000 | 4.06 | — |
| Sergio Traversa | Option | 700,000 | 0.67 | — |
| Maged Shenouda | Option | 41,045 | 2.48 | — |
| Charles Ence | Option | 125,000 | 3.37 | — |
| Charles Ence | Option | 828,000 | 4.06 | — |
| Paul Kelly | Option | 37,500 | 3.37 | — |
| Paul Kelly | Option | 350,000 | 0.67 | — |
Our compensation programs are designed to attract, motivate and retain qualified and talented executives, motivating them to achieve our business goals and rewarding them for superior short- and long-term performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Radford |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-24 | 7,529,377 | 10,119,590 | 26,154 | 42.66% | Failed |
| 2021 | 2021-05-20 | 10,410,272 | 735,198 | 75,145 | 93.4% | Passed |
| 2018 | 2018-02-02 | 4,250,455 | 248,565 | 38,032 | 94.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-05-24 | 42.66%a |
| 2021 | 2021-05-20 | 93.4%b |
| 2018 | 2018-02-02 | 94.48%c |
a. Approved under the standard stated in the filing — “Abstentions will not be counted in determining the number of votes cast in connection with any matter presented at the annual meeting.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted in determining the number of votes cast in connection with any matter presented at the annual meeting.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Paul KellyEmployee director | $70,620 | $0 | $0 | — | $802,160 | $872,780 |
| Charles J. CasamentoIndependent · Board Chair · Audit · Corporate Governance and Nominating · Compensation (Chair) · Corporate Governance · Nominating | 173,608 | 0 | 0 | — | 180,000 | 353,608 |
| Fabiana FedeliIndependent · Audit · Corporate Governance and Nominating · Compensation | 110,638 | 0 | 0 | — | 180,000 | 290,638 |
| John GlasspoolIndependent · Audit · Corporate Governance and Nominating · Compensation · Corporate Governance (Chair) · Nominating (Chair) | 106,518 | 0 | 0 | — | 180,000 | 286,518 |
| Sergio TraversaEmployee director | — | — | — | — | — | 0 |
| Charles EnceEmployee director · Newly elected | — | — | — | — | — | — |
| Maged ShenoudaEmployee director · Audit · Compensation · Corporate Governance and Nominating · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $74,152 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 24,717 / 17,919 / 17,919 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $461,384 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $1,342,160 |
| Total cost of the board | $1,803,544 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics | 2025 | Sergio Traversa | $787,787 | $0 | $4,951,301 | $0 | $8,892,633 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sergio Traversa | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 8,892,633. Filing ↗machine: r1 · c17 · span 518846–518855 |
| 2 | Section 01, Maged Shenouda | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 6,091,453. Filing ↗machine: r3 · c17 · span 541215–541224 |
| 3 | Section 01, Charles Ence | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 5,497,026. Filing ↗machine: r5 · c17 · span 563208–563217 |
| 4 | Section 01, Paul Kelly | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 5,289,099. Filing ↗machine: r7 · c17 · span 585972–585981 |
| 5 | Section 08, Paul Kelly | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 872,780. Filing ↗machine: span 326949–327328 |
| 6 | Section 08, Charles J. Casamento | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 353,608. Filing ↗machine: span 317134–317513 |
| 7 | Section 08, Fabiana Fedeli | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 290,638. Filing ↗machine: span 346449–346828 |
| 8 | Section 08, John Glasspool | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 286,518. Filing ↗machine: span 336709–337088 |
| 9 | Section 08, Sergio Traversa | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 08, Charles Ence | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: —. Filing ↗machine: span 562846–563227 |
| 11 | Section 08, Maged Shenouda | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: —. Filing ↗machine: span 540853–541234 |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-05-30 | 0001213900-24-047968 | Item 5.07 · say-on-pay result. As reported: 42.66% (votes for as printed: 7,529,377). Filing ↗ |
| 13 | Section 06, 2021 vote | Form 8-K | 2021-05-20 | 0001213900-21-028217 | Item 5.07 · say-on-pay result. As reported: 93.4% (votes for as printed: 10,410,272). Filing ↗ |
| 14 | Section 06, 2018 vote | Form 8-K | 2018-02-05 | 0001213900-18-001309 | Item 5.07 · say-on-pay result. As reported: 94.48% (votes for as printed: 4,250,455). Filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 461,384 + equity 0 + all other 1,342,160 = 1,803,544, summed across the director compensation table rows.machine: formula: Σ = 1,803,544 |
| 17 | Relmada Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045192 | CEO total compensation as printed in Relmada Therapeutics's own proxy. As printed: 8,892,633. Filing ↗machine: r1 · c17 · span 518846–518855 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
We'll email you a link to confirm.